Opioid sponsors may be able to avoid fronting the cost of creating a new national prescribing database for providers to check for potential patient misuse and abuse of the medications, should the US FDA decide such a system is necessary.
While some speakers during a Jan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?